跳至主要内容
临床试验/NCT01332539
NCT01332539已完成不适用

An Observational Study to Assess the Burden of Drug-resistant Partial Epilepsy in Italy

GlaxoSmithKline0 个研究点目标入组 240 人开始时间: 2011年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
240
主要终点
total cost (direct and indirect) per patient per year of drug-resistant partial patients collected in the retrospective and in the prospective phase

研究概览

简要总结

observational, non-interventional study in 120 patients with drug-resistant partial epilepsy, comprising two phases: a 3-month retrospective and a 6-month prospective. As control group, 120 patients with controlled partial epilepsy will be enrolled. The objective of the study is to describe the burden of illness in this epileptic population both in terms of costs and of quality of life. Costs and quality of life will be also compared between the two populations.

详细描述

observational, non-interventional study in 120 patients with drug-resistant partial epilepsy, comprising two phases: a 3-month retrospective and a 6-month prospective.

研究设计

研究类型
Observational
观察模型
Cohort

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Outpatients
  • Diagnosis of partial epilepsy, defined as active, drug-resistant in accordance to the 2010 ILAE (International League Against Epilepsy) definition and actually taking an add-on therapeutic regimen.
  • Able and willing to give the written informed consent (to be obtained before any study assessment)
  • For each drug-resistant patient, will be enrolled a patient with the same diagnosis and actually taking an add-on therapy but with controlled epilepsy according to the 2010 ILAE definition.

排除标准

  • Patient currently included in a clinical trial for an AED (Anti-Epileptic Drug)
  • Hospital record data on epilepsy not available in the Investigator's files
  • Patient unable to fill in self-questionnaires (quality of life instrument)
  • Patient currently hospitalized
  • Patient who, according to the Investigator's judgment, is not able to follow the study procedures

结局指标

主要结局

total cost (direct and indirect) per patient per year of drug-resistant partial patients collected in the retrospective and in the prospective phase

时间窗: 9 months: a 3-month retrospective and a 6-month prospective.

次要结局

  • The primary endpoint is the total cost (direct and indirect) per patient per year of controlled patients collected in the retrospective and in the prospective phase.(9 months. a 3-month retrospective and a 6-month prospective.)
  • the difference between the group of drug-resistant patients and the control group as regards each single resource consumptions and the direct and indirect costs (single and total)(9 months: a 3-month retrospective and a 6-month prospective.)
  • The comparison of the seven multi-item scores and the overall score of QOLIE-31 (Quality of life in Epilepsy -31 items) questionnaire between the two patients groups(questionnaire administerd at visit 1 only)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验